A number of other research analysts also recently issued reports on BRKR. Leerink Swann upgraded shares of Bruker from a market perform rating to an outperform rating in a research note on Friday, May 3rd. Needham & Company LLC lifted their price target on shares of from $50.00 to $53.00 in a research note on Monday, June 24th. Svb Leerink reiterated an outperform rating on shares of Arcus Biosciences in a research note on Friday, May 3rd. Wolfe Research assumed coverage on shares of Waters in a report on Thursday, May 30th. They set an underperform rating on the stock. Finally, Jefferies Financial Group reissued a buy rating on shares of Linde in a report on Friday, June 21st. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Bruker currently has an average rating of Buy and an average target price of $48.18.
Shares of Bruker stock opened at $48.35 on Tuesday. Bruker has a 52-week low of $26.10 and a 52-week high of $51.41. The business has a 50 day moving average price of $47.48. The company has a quick ratio of 1.27, a current ratio of 2.12 and a debt-to-equity ratio of 0.42. The stock has a market capitalization of $7.58 billion, a P/E ratio of 34.54, a P/E/G ratio of 2.37 and a beta of 1.32.
The business also recently disclosed a quarterly dividend, which was paid on Friday, June 21st. Shareholders of record on Monday, June 3rd were issued a dividend of $0.04 per share. The ex-dividend date of this dividend was Friday, May 31st. This represents a $0.16 dividend on an annualized basis and a yield of 0.33%. Bruker’s payout ratio is currently 11.43%.
In other news, Director Marc A. Kastner sold 1,374 shares of Bruker stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $41.79, for a total value of $57,419.46. Following the transaction, the director now directly owns 10,811 shares of the company’s stock, valued at approximately $451,791.69. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Frank H. Laukien sold 400,000 shares of Bruker stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $41.48, for a total transaction of $16,592,000.00. Following the completion of the transaction, the chief executive officer now directly owns 37,991,030 shares in the company, valued at $1,575,867,924.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 801,374 shares of company stock worth $33,241,419. 26.50% of the stock is owned by corporate insiders.
Institutional investors have recently made changes to their positions in the company. O Shaughnessy Asset Management LLC acquired a new position in shares of Bruker in the 1st quarter valued at $35,000. Captrust Financial Advisors increased its holdings in shares of Bruker by 164.7% in the 4th quarter. Captrust Financial Advisors now owns 1,824 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 1,135 shares during the period. Machina Capital S.A.S. acquired a new position in shares of Bruker in the 2nd quarter valued at $132,000. New York State Teachers Retirement System acquired a new position in shares of Bruker in the 2nd quarter valued at $150,000. Finally, ARP Americas LP acquired a new position in shares of Bruker in the 1st quarter valued at $212,000. 66.73% of the stock is currently owned by institutional investors and hedge funds.
Bruker Company Profile
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
Featured Article: How is a price target determined?
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.